Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

被引：44

作者：

Stahl, Stephen M. ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
,10
,11
,12
,13
,14
,15
,16
,17
,18
,19
,20
,21
,22
,23
,24
,25
,26
,27
,28
,29
,30
,31
,32
,33
,34
,35
,36
,37
,38
,39
,40
,41
,42
,43
,44
,45
,46
,47
,48
,49
,50
,51
,52
,53
,54
,55
,56
,57
,58
]}

机构：

[1] Univ Calif San Diego, Psychiat, La Jolla, CA 92093 USA

[2] Univ Cambridge, Cambridge, England

[3] Calif Dept State Hosp, Psychopharmacol, Sacramento, CA 95814 USA

[4] Acadia, San Diego, CA USA

[5] Adamas, Emeryville, CA USA

[6] Alkermes, Dublin, Ireland

[7] Allergan, Dublin, Ireland

[8] Arbor Pharmaceutcials, Atlanta, GA USA

[9] AstraZeneca, Cambridge, England

[10] Avanir, Aliso Viejo, CA USA

[11] Axovant, Hamilton, Bermuda

[12] Axsome, New York, NY USA

[13] Biogen, Cambridge, MA USA

[14] Biomarin, Novato, CA USA

[15] Biopharma, Cary, NC USA

[16] Celgene, Summit, NJ USA

[17] Concert, Bristol, Avon, England

[18] ClearView, Princeton, NJ USA

[19] DepoMed, Newark, CA USA

[20] Dey, Wayne, NJ USA

[21] EnVivo, Watertown, MA USA

[22] EMD Serono, Rockland, MA USA

[23] Ferring, St Prex, Switzerland

[24] Forest, New York, NY USA

[25] Forum, Watertown, MA USA

[26] Genomind, King Of Prussia, PA USA

[27] Innovat Sci Solut, Morristown, NJ USA

[28] Intra Cellular Therapies, New York, NY USA

[29] Janssen, Beerse, Belgium

[30] Jazz, Dublin, Ireland

[31] Lilly, Indianapolis, IN USA

[32] Lundbeck, Copenhagen, Denmark

[33] Merck, Kenilworth, NJ USA

[34] Neos, Grand Prairie, TX USA

[35] Novartis, Basel, Switzerland

[36] Noveida, New York, NY USA

[37] Orexigen, La Jolla, CA USA

[38] Otsuka, San Francisco, CA USA

[39] PamLabs, Carlsbad, CA USA

[40] Perrigo, Dublin, Ireland

[41] Pfizer, New York, NY USA

[42] Pierre Fabre, Paris, France

[43] Reviva, Paris, France

[44] Servier, Neuilly Sur Seine, France

[45] Shire, Lexington, MA USA

[46] Sprout, Chicago, IL USA

[47] Sunovion, London, England

[48] Taisho, Toshima, Tokyo, Japan

[49] Taliaz, Tel Aviv, Israel

[50] Teva, Petah Tiqwa, Israel

来源：

CNS SPECTRUMS | 2019年 / 24卷 / 05期

关键词：

MAJOR DEPRESSIVE DISORDER; ANTIDEPRESSANT MEDICATIONS; AMPA RECEPTORS; PATHOPHYSIOLOGY; LEVOMETHORPHAN; KETAMINE;

D O I：

10.1017/S1092852919001470

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) antagonist esketamine given intranasally for treatment-resistant depression has reinforced the need for agents with rapid onset with alternate mechanisms of action. Dextromethorphan/bupropion, an investigational medicine currently in development, is one such candidate.

引用

页码：461 / 466

页数：6

共 50 条

[41] Characterization of the N-methyl-d-aspartate (NMDA) receptor in the embryonic chick brain
S. O. P. Jacobsson
Henrietta Hedin
Åke Sellström
Christopher J. Fowler
Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357 : 625 - 633
[42] Ontogeny of the N-methyl-D-aspartate (NMDA) receptor system and susceptibility to neurotoxicity
Haberny, KA
Paule, MG
Scallet, AC
Sistare, FD
Lester, DS
Hanig, JP
Slikker, W
TOXICOLOGICAL SCIENCES, 2002, 68 (01) : 9 - 17
[43] CEREBROVASCULAR AND METABOLIC CONSEQUENCES OF N-METHYL-D-ASPARTATE (NMDA) RECEPTOR BLOCKADE
MCCULLOCH, J
KURUMAJI, A
PARK, CK
NEHLS, DG
NEUROTRANSMISSION AND CEREBROVASCULAR FUNCTION, VOL 1, 1989, 869 : 449 - 452
[44] Characterization of the N-methyl-D-aspartate (NMDA) receptor in the embryonic chick brain
Jacobsson, SOP
Hedin, H
Sellström, Å
Fowler, CJ
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (06) : 625 - 633
[45] MEMANTINE IS A POTENT BLOCKER OF N-METHYL-D-ASPARTATE (NMDA) RECEPTOR CHANNELS
BORMANN, J
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 166 (03) : 591 - 592
[46] INFLUENCING CHONDROGENESIS VIA THE N-METHYL-D-ASPARTATE (NMDA) RECEPTOR PATHWAY
Zakany, R.
Juhasz, T.
Fodor, J.
Takacs, R.
Vago, J.
Csernoch, L.
Matta, C.
OSTEOARTHRITIS AND CARTILAGE, 2020, 28 : S104 - S105
[47] Implication of Genes for the N-Methyl-d-Aspartate (NMDA) Receptor in Substance Addictions
Chen, Jiali
Ma, Yunlong
Fan, Rongli
Yang, Zhongli
Li, Ming D.
MOLECULAR NEUROBIOLOGY, 2018, 55 (09) : 7567 - 7578
[48] Implication of Genes for the N-Methyl-d-Aspartate (NMDA) Receptor in Substance Addictions
Jiali Chen
Yunlong Ma
Rongli Fan
Zhongli Yang
Ming D. Li
Molecular Neurobiology, 2018, 55 : 7567 - 7578
[49] A novel glycine site-specific N-methyl-D-aspartate receptor antagonist prevents activation of the NMDA/NO/CGMP pathway by ammonia
Hilgier, W
Oja, SS
Saransaari, P
Albrechta, J
BRAIN RESEARCH, 2004, 1015 (1-2) : 186 - 188
[50] Novel pyrrolinones as N-methyl-D-aspartate receptor antagonists
Poschenrieder, H
Stachel, HD
Höfner, G
Mayer, P
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2005, 40 (04) : 391 - 400

← 1 2 3 4 5 →